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Abstract
Background: Patients with chronic kidney disease (CKD) due to glomerulonephritis (GN) are thought to be at high
risk for cardiovascular disease (CVD). However, no study has examined whether GN directly contributes to CV risk
beyond the effects conferred by pre-existing traditional risk factors and level of renal function.
Methods: Matched cohort study using the previously described prospective CanPREDDICT study cohort. 2187 patients
with CKD (eGFR 15–45 ml/min/m2) from 25 Canadian centres were divided into GN vs non-GN cause of CKD. Patients
on immunotherapy for GN were not included in the study. Standardized measures of CV risk factors, biomarkers and
CV outcomes were recorded over 3 years of follow-up, with the primary outcome measure being time to first all-cause
CV event.
Results: In the overall cohort, CV events occurred in 25 (8.7%) of the GN group and 338 (17.8%) of the non-GN group
(HR 0.45, 95% CI 0.30–0.67, p < 0.01). In a Cox regression multivariable model that included age, sex, prior diabetes and
CVD, baseline eGFR and onset of renal replacement therapy, the risk of CV events was similar in the GN and non-GN
groups (HR 0.71, 95% CI 0.47–1.08, p = 0.11). GN and non-GN patients were matched by age and using a propensity
score including sex, prior diabetes and CVD and baseline eGFR. In the matched group, the risk of CV events was similar
in GN vs non-GN patients (N = 25/271 (9.2%) in both groups, HR 1.01, 95% CI 0.05–1.77, p = 0.9). An interaction analysis
showed that CRP, ACR and troponin conferred differing amounts of CV risk in the GN and non-GN groups.
Conclusions: Patients with advanced CKD due to GN have a high 8.7% absolute 3-year risk of CVD, attributable to prior
CV risk factors and level of kidney function rather than the GN disease itself.
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Background
Patients with glomerulonephritis (GN) have been trad-
itionally characterised as being at high risk of cardiovas-
cular disease (CVD), and this has been recently
reiterated in the 2012 KDIGO GN guidelines [1]. GN
patients are recognised to develop traditional epidemio-
logic risk factors for CVD, including hypertension and
hyperlipidemia [2–4], as well as novel CV risk factors
such inflammation, endothelial dysfunction and protein-
uria [2, 5–7]. In addition, GN patients frequently
develop chronic kidney disease (CKD) with impaired
kidney function. Irrespective of cause, CKD is associated
with a high risk of CVD and CV death [8–10]. Prior
studies investigating CVD in GN have not accounted for
these risk factors [2, 11, 12], and as such it remains
unknown whether the high risk of CVD in GN patients
is attributable to the disease itself or to the presence of
concurrent CVD risk factors and CKD with low renal
function.
CanPREDDICT is a prospective Canadian cohort
study of 2544 patients with GN and non-GN CKD with
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standardized assessment of CV risk factors, CVD out-
comes and biomarkers of inflammation, endothelial dys-
function and proteinuria. We used the CanPREDDICT
cohort to examine our primary hypothesis that the risk
of CVD over 3 years in patients with GN is higher com-
pared to those with non-GN causes of CKD, after
accounting for traditional CVD risk factors and renal
function. Because novel CV risk factors are proposed to
be uniquely important in glomerular diseases [7, 13, 14],
we additionally explored whether the association be-
tween CVD risk and proteinuria or biomarkers of
inflammation and endothelial dysfunction is different in
patients with GN compared to non-GN CKD.
Methods
Details of the CanPREDDICT study have been previously
described [15]. In brief, 2544 patients with CKD (eGFR
15–45 ml/min/m2) from 25 Canadian centres were re-
cruited from 2008 to 2009, and were prospectively
followed for 3 years for CV outcomes with standardized
measurements of multiple biomarkers. Patients with GN
on immunosuppression were specifically excluded from
CanPREDDICT. We included in our analysis those pa-
tients from the CanPREDDICT study with no missing
demographic or biomarker data at baseline and with a
known cause of primary kidney disease.
Data collection
All patients were categorized into 2 groups (GN and
non-GN) based on their primary renal diagnosis pro-
vided at the time of recruitment into the CanPREDDICT
cohort. The cause of primary kidney disease was chosen
from a list of options by the nephrologist at the time of
recruitment into the study, with qualifying descriptions
provided in free text format. An investigator (HH)
blinded to other data and outcome status reviewed the
renal diagnosis details to classify patients into non-GN
or GN groups. GNs were further categorized as IgA ne-
phropathy, membranous nephropathy, lupus nephritis,
anti-neutrophil cytoplasmic antibody (ANCA) associated
vasculitis, focal segmental glomerulosclerosis (FSGS) or
GN unspecified. Demographics, medications, blood
pressure (BP) and comorbidities were collected at base-
line and every 6 months over the 3-year study period.
Blood and urine samples were collected at baseline. Pro-
teinuria was assessed using urine albumin to creatinine
ratio (uACR). Biomarkers known to be associated with
CVD in the general CKD population were measured as
previously described, including high sensitivity C-
reactive protein (CRP) [16], troponin I [17], asymmetric
dimethylarginine (ADMA) [18], interleukin-6 (IL-6) [19]
and N-terminal pro-brain natriuretic peptide (ProBNP)
[15–17].
Definitions of outcomes
The primary outcome was the first occurrence of an all-
cause CV event. All CV outcomes were centrally adjudi-
cated based on source documentation by a blinded panel
of three investigators using standardized definitions as
previously described [15]. An all-cause CV event was
defined as fatal or non-fatal myocardial infarction (MI),
need for coronary revascularization (coronary artery
bypass graft/percutaneous coronary intervention/percu-
taneous transluminal coronary angioplasty), ischemic
stroke or congestive heart failure.
Statistical analysis
Analysis of the primary outcome was based on the time
from entry in the CanPREDDICT study to the first oc-
currence of an all-cause CV event, censored at death or
the end of follow-up.
Comparing the risk of CV events in GN compared to non-
GN CKD patients in the non-matched cohort
Survival without the primary CV endpoint was described
in GN vs non-GN patients using the Kaplan Meier
method and compared using the long-rank test. To con-
trol for renal function and traditional CV risk factors,
we used Cox regression multivariable models that in-
cluded GN vs non-GN CKD, age, sex, prior diabetes and
CVD, baseline eGFR and onset of RRT as a time-
dependent variable (to account for any confounding ef-
fect of differential progression to end stage renal disease
on the risk of CV events).
Comparing the risk of CV events in GN to a matched cohort
of non-GN CKD patients
We matched GN to non-GN patients using a stepwise
approach: first direct matching on age (+/− 2.5 years),
and second using a propensity score that included gen-
der, history of diabetes, CVD and baseline eGFR. Match-
ing was 1:1 using a calliper width of 0.25 standard
deviation and a best-overall fit algorithm. Using the
matched cohort, time to first all-cause CV event cen-
sored at death or end of follow-up was compared in GN
vs non-GN CKD patients using a shared frailty Cox
model to account for clustering on matched pairs.
Comparing the association of select biomarkers and CV risk
in GN and non-GN patients
To investigate differences in the association between se-
lect biomarkers and CV risk in the GN and non-GN
groups, an interaction term between each biomarker and
disease type was included with the main effects in the
matched cohort models. Using these models, we
expressed the hazard ratios for the association between
each biomarker and CVD separately in the GN and non-
GN groups.
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Because of the significant impact of diabetes on CVD
risk, we performed stratified analyses in which the
matching algorithm and analysis were repeated in sub-
groups with and without diabetes to explore consistency
of results. The existing literature suggests that hyperten-
sion and dyslipidemia may be both directly caused by
GN and result in CVD [4, 11, 14, 20–22]. As such, these
two variables can be considered in the causal pathway
between GN and CVD, and so we did not include them
in our primary analyses. However, we performed a sensi-
tivity analysis that included adjustment for both blood
pressure and cholesterol levels. Variables with highly
skewed distributions were transformed to the natural
logarithm scale. Categorical variables were described as
frequency (count) and compared across groups using
Fischer’s exact test. Continuous variables with normal
distributions were described as mean [standard devi-
ation] and compared across groups using the t-test, and
variables with non-normal distributions were described
as median [interquartile range, IQR] and compared
using the Wilcoxon Rank Sum test. All analyses were
performed using SAS software, version 9.3 (SAS Institute
Inc., Cary, NC, USA) and R software, version 3.1.0. All
tests were two-sided with P-values <0.05 considered sta-
tistically significant.
Results
There were 2544 patients in the CanPREDDICT study
with 2187 in the analytic cohort, including 288 with GN
and 1899 with non-GN CKD (see Fig. 1). Baseline char-
acteristics of the cohort in the GN compared to non-GN
patients are shown in Table 1. GN patients had less
traditional CV risk factors, with younger age (58.9 vs
69.7 years, p < 0.01), less frequent diabetes (20% vs 54%,
p < 0.001) and prior history of CVD (28% vs 47%, p <
0.01), and lower mean systolic BP (131 vs 134 mmHg, p
< 0.01). GN patients had significantly higher uACR (59.5
vs 14.4 mmol/L, p < 0.01) and total cholesterol (179 vs
161 mg/dL, p = 0.03); lower ProBNP (273 vs 511 pg/mL,
p < 0.01), IL-6 (3.04 vs 4.54, p < 0.01) and CRP (2.2 vs
3.0, p < 0.01) but similar eGFR (27.1 vs 27.7 ml/min/
1.73 m2). Progression to RRT during follow-up was
more common in the GN compared to non-GN group
(25.4% vs 15.8%, p < 0.01).
The risk of CVD in GN vs non-GN CKD patients in the
non-matched cohort
There were a total of 363 CV events in the entire cohort
over the 3-year period, with 25 events in the GN group
(8.7%), and 338 events (17.8%) in the non-GN group.
The most common event was fatal or non-fatal MI (N =
166, including 9 GN and 157 non-GN), followed by
CHF (N = 122, including 8 GN and 114 non-GN), stroke
(N = 51, including 5 GN and 46 non-GN) and coronary
revascularization (N = 24, including 3 GN and 21 non-
GN). Figure 2a outlines the CV event free survival in
GN compared to non-GN patients. GN patients had su-
perior CV event free survival compared to non-GN pa-
tients (unadjusted HR = 0.45, 95% CI 0.3–0.67, p < 0.01).
Table 2 displays the result of the multivariate model for
the risk of CV event in GN versus non-GN patients.
After adjustment for potential measured confounders,
the risk of CV events was similar in the two groups (HR
= 0.71, 95% CI 0.47–1.08, p = 0.11). In a sensitivity
analysis, when mean arterial blood pressure and total
Fig. 1 Flow diagram of patients included in the analytic cohort
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cholesterol were added to the model the results were un-
changed (data not shown).
The risk of CVD in GN compared to a matched cohort of
non-GN CKD patients
To further control for renal function and CV risk factors
in the association of GN and CV risk, we matched 272
patients from the GN group with 272 patients from the
non-GN group based on age, sex, eGFR and prior dia-
betes and CVD. Characteristics of the matched cohort
are shown in Table 3. Differences in age, BP, prior dia-
betes and CVD and total cholesterol between GN and
non-GN patients that were seen in the overall cohort
were no longer present after matching. GN patients had
higher uACR (58.7 vs 17.2 mg/mmol, p < 0.01) and lower
serum albumin (40 vs 41 g/L p < 0.01), but there were
no significant differences in troponin I, IL-6, Pro-BNP,
ADMA or CRP between the groups (Table 3). Progres-
sion to RRT during follow-up occurred in 24.6% of the
non-GN group and 25.4% of the GN group (p = 0.84) in
the matched cohort.
The frequency of CV events over 3 years in the
matched cohort was 9.2% (N = 25) in both the GN and
non-GN groups. Figure 2b shows that the CV event free
survival was similar in the GN patients compared to the
matched cohort of non-GN patients (log-rank p-value
0.96). The risk of CV events was similar in the GN com-
pared to non-GN patients in both univariable (HR 1.01,
95% CI 0.58–1.77, p = 0.96) and multivariable models
(HR 0.99, 95% CI 0.56–1.75, p = 0.96, see Table 4).
Because of residual differences in proteinuria between
the groups after matching, we additionally added uACR
to the multivariable model which did not change our re-
sults (GN vs non-GN HR 0.87, 95% CI 0.49–1.58, p =
0.66). In a sensitivity analysis, when mean arterial blood
pressure and total cholesterol were added to the model
the results were unchanged (data not shown).
We repeated the matching and analysis in diabetic and
non-diabetic subgroups. Of the 112 matched patients
with diabetes, 21.4% (n = 12) of both the GN and non-
GN patients had a CV event. Of the 388 matched
patients without diabetes, CV events occurred in 6.2%
(N = 12) and 8.2% (N = 16) in the GN and non-GN
groups respectively. In multivariable models, there was
Table 1 Characteristics of the GN and non-GN patients in the
cohort. Data are presented as mean ± standard deviation (SD),
median (IQR) or count (frequency)




39.0 (33.5–39.0) 39.0 (22.5–39.0)
Age (years) 58.9 ± 15.1 69.7 ± 11.7 <0.001
Male (%) 189 (66%) 1184 (62%) 0.3
Caucasian (%) 241 (84%) 1703 (90%) <0.001
Primary cause of
kidney disease (%)
Diabetes - 777 (41%)
Hypertension - 823 (48%)
PCKD - 108 (6%)
Other non-GN - 252 (13%)
GN subtypes (%)
IgA Nephropathy 61 (21%) -
FSGS 35 (12%) -
ANCA Vasculitis 21 (7%) -




GN Unspecified 149 (52%) -
Diabetes (%) 58 (20%) 1025 (54%) <0.001
CVD history (%) <0.001
No CVD 206 (72%) 998 (53%)
Ischemic HD 33 (12%) 365 (17%)
CHF 29 (10%) 215 (11%)
Ischemic and CHF 20 (7%) 321 (17%)
Mean eGFR (ml/min/
1.73 m2) ++/SD
27.1 ± 9.1 27.7 ± 8.9 0.3
eGFR categories (%) 0.1
< 20 ml/min 81 (28%) 428 (23%)
20–29 107 (37%) 757 (40%)
> 30 100 (35%) 714 (40%)
uACR (mg/mmol) 59.5 [13.7–172.3] 14.4 [2.9–76.8] <0.001
Systolic BP
(mmHg)
131 ± 18 134 ± 20 <0.001
Diastolic BP
(mmHg)
75 ± 12 70 ± 12 <0.001
Albumin (g/L) 40.0 ± 4.8 40.4 ± 4.2 0.08
Total cholesterol
(mg/dL)
4.6 ± 1.2 4.2 + 1.1 0.03
Elevated Troponin
I (% > LLD)
71 (25%) 714 (38%) <0.001
CRP (mg/mL) 2.2 [0.9–5.3] 3.0 [1.2–6.9] <0.001
ADMA 0.54 ± 0.94 0.55 ± 0.12 0.1
IL-6 (μg/L) 3.04 [1.00–5.80] 4.54 [1.00–7.25] <0.001
Table 1 Characteristics of the GN and non-GN patients in the
cohort. Data are presented as mean ± standard deviation (SD),
median (IQR) or count (frequency) (Continued)
NT-ProBNP (pg/
mL) Pg/mL
273 [119–727] 511 [213–1485] <0.001
Abbreviations: PCKD polycystic kidney disease, FSGS focal segmental
glomerulosclerosis, CVD cardiovascular disease, CHF congestive heart failure,
BP blood pressure, LLD lower limit of detection, ADMA asymmetric
dimethylarginine, IL-6 interleukin 6, NT-Pro-BNP N-terminal pro-brain
natriuretic peptide
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no difference in the risk of CV events between GN and
non-GN patients in either the diabetic or non-diabetic
subgroups (data not shown).
Biomarkers as CV risk factors in GN compared to matched
non-GN CKD patients
Using the matched cohort, we explored whether the risk
of CVD associated with ACR, CRP, IL-6, ADMA, tropo-
nin I and ProBNP was different in the GN compared to
non-GN groups using interaction terms. The hazard ra-
tios for each biomarker by GN group are presented in
Table 5 and main effects in Additional file 1: Table S1.
Although the interaction terms were not statistically sig-
nificant (p-values 0.06–0.94), there was a suggestion of
quantitative differences in the hazard ratios for uACR,
CRP and troponin I in the GN compared to non-GN
groups (interaction p-values 0.15, 0.24 and 0.06 respect-
ively). The hazard ratio for the association between
uACR and CV risk was higher and statistically signifi-
cant in the non-GN group but not in the GN group. In
Fig. 2 The probability of survival without an all-cause CV event in GN compared to non-GN patients in a) the overall cohort prior to matching
(log-rank p-values <0.01), and b) in the matched cohort (log-rank p-values = 0.96)
Table 2 The results of univariable and multivariable Cox regression




GN vs non-GN CKD 0.45 0.30–0.67 <0.001
Multivariable Model
GN vs non-GN CKD 0.71 0.47–1.08 0.1
Age 1.03 1.02–1.04 <0.001
Male sex 1.05 0.85–1.31 0.6
Diabetes 1.71 1.37–2.13 <0.001
Prior CVD 2.28 1.82–2.87 <0.001
Baseline eGFR 0.97 0.96–0.99 <0.001
RRTa 2.01 1.38–2.93 <0.001
a as a time-dependent variable
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comparison the opposite was true for CRP, which was
associated with CV risk only in GN patients. Troponin I
was a strong risk factor for CVD in both groups, but the
magnitude of risk was three times greater in non-GN
compared to GN patients.
Discussion
Although guidelines state that GN patients should be
considered high risk for CVD [1], this is based on con-
flicting studies that did not account for renal function,
and therefore the contribution of CKD and pre-existing
traditional risk factors to CVD risk in glomerular dis-
eases remained unknown. In order to address this defi-
ciency, we used a large prospective CKD cohort with
Table 3 Characteristics of matched GN and non-GN groups. Results
are presented as mean ± standard deviation, median (IQR) or count
(frequency)
Variable GN Non-GN P value
Number 272 272
Median follow up 39.0 (33.2–39.0) 39.0 (33.8–39.0)
Age (years) 60.5 ± 14 60.4 ± 14 0.9
Male 177 (65%) 177 (65%) 0.9
Caucasian 231 (85%) 242 (89%) 0.4
Cause of Kidney
Disease
Diabetic - 49 (18%)
Hypertensive - 87 (32%)
PCKD - 44 (16%)
Other non-GN - 92 (34%)
IgA 60 (22%) -
FSGS 33 (12%) -
ANCA Vasculitis 21 (8%) -
Lupus 13 (5%) -
Membranous Nephritis 9 (3%)
GN unspecified 136 (50%)
Diabetes 57 (21%) 60 (22%) 0.7
CVD history 0.9
No CVD 193 (71%) 201 (74%)
Ischemic 33 (12%) 30 (11%)
CHF 27 (10%) 25 (9%)
Ischemic and CHF 19 (7%) 16 (6%)
eGFR (ml/min/1.73 m2) 27.0 ± 9.1 27.2 ± 9.1 0.8
eGFR categories 0.7
< 20 76 (28%) 68 (25%)
20–29 103 (38%) 109 (40%)
> 30 93 (34%) 95 (35%)
ACR (mg/mmol) 58.7 [13.6, 170.2] 17.2 [3.6–90.0] <0.001
Systolic BP (mmHg) 132 ± 19 131 ± 19 0.8
Diastolic BP (mmHg) 75 ± 12 74 ± 12 0.4
Statin 158 (58%) 147 (54%) 0.3
Albumin (g/L) 39.8 ± 4.8 41.1 ± 4.2 <0.001
Total cholesterol (mg/dL) 4.7 ± 1.2 4.5 ± 1.4 0.4
Troponin I (> LLD) 71 (26%) 68 (25%) 0.8
CRP (mg/mL) 2.4 [0.9–5.6] 2.4 [1.1–5.5] 0.6
ADMA 0.537 ± 0.094 0.534 ± 0.151 0.9
IL-6 (μg/L) 3.55 [1.00–6.02] 3.5 [1.00–5.27] 0.6
NT-ProBNP
(pg/mL) Pg/mL
299 [121–799] 291 [107–757] 0.7
Abbreviations: PCKD polycystic kidney disease, FSGS focal segmental
glomerulosclerosis, CVD cardiovascular disease, CHF congestive heart failure,
BP blood pressure, LLD lower limit of detection, ADMA asymmetric
dimethylarginine, IL-6 interleukin 6, NT-Pro-BNP N-terminal pro-brain
natriuretic peptide
Table 4 The results of univariable and multivariable shared frailty




GN vs non-GN CKD 1.01 0.58–1.77 0.9
Multivariable Model
GN vs non-GN CKD 0.99 0.56–1.75 0.9
Age 1.03 1.01–1.07 0.03
Male sex 1.27 0.63–2.55 0.5
Diabetes 3.11 1.59–6.07 <0.001
Prior CVD 3.16 1.55–6.46 <0.001
Baseline eGFR 1.01 0.98–1.05 0.4
RRT a 1.51 0.51–4.50 0.4
a as a time-dependent variable
Table 5 In the matched cohort, the association between each
biomarker and the risk of all-cause CV events in the GN and non-GN
groups using multivariable models that included interaction terms
between the GN vs non-GN group and each biomarker
Biomarker HR 95% CI
uACR (per log unit) GN 1.02 0.81–1.30
Non-GN 1.30 1.03–1.62
ADMA (per 1StD) GN 1.54 0.95–2.50
Non-GN 1.06 0.82–1.37
ProBNP (per 1StD) GN 2.21 1.43–3.40
Non-GN 2.54 1.68–3.86
CRP (per 1StD) GN 1.70 1.11–2.60
Non-GN 1.22 0.81–1.84






uACR, ProBNP, CRP and IL6 were log-transformed for analysis
Abbreviations: LLD lower limit of detection, StD standard deviation
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standardized measures of CV risk factors and outcome
events to investigate the risk of CVD in GN compared
to non-GN patients matched for renal function and
prior CV risk factors. We show that GN patients are at a
high 9.2% absolute risk of CVD over 3 years, but that in
contrast to our a priori hypothesis this risk was not
different from otherwise comparable patients with ad-
vanced CKD without GN. These results suggest that
once a sustained reduction in kidney function has
developed, GN is not independently associated with add-
itional CV risk beyond that explained by reduced eGFR
and pre-existing traditional risk factors.
The assumption that primary GN is linked to an
increased risk of vascular events derives from older case
series with conflicting results, ranging from no increased
risk to an 85 fold relative risk of CVD compared to the
general population [20, 23–27]. More recent cohort
studies described a more attenuated 2–8 fold relative
risk in CVD, but none accounted for traditional CV risk
factors or the degree of renal dysfunction [2, 4, 11, 12,
28]. The association of eGFR with CVD has been well
established in both the general CKD and GN populations
[2, 4, 5, 9, 10]. This is the first study to systematically com-
pare GN to non-GN patients while considering both base-
line eGFR and prior traditional CV risk factors. In
unadjusted analysis, the GN patients had a significantly
lower risk of CV events compared to the non GN patients,
likely due to their younger age and comparative lack of
traditional CV risk factors. However, after accounting for
age, sex, diabetes, prior CVD and eGFR using two differ-
ent methods (multivariable adjusted models and a two-
stage propensity score matching algorithm), we showed
that CKD patients with GN had a similar risk of CVD
compared to non-GN patients. Because our results were
unchanged when we adjusted for RRT, our findings are
not likely confounded by differential rates of progression
to ESRD. In our primary analyses we did not adjust for
blood pressure and dyslipidemia because these may both
mediate the risk of CVD that results from GN. However,
in sensitivity analyses that included both of these variables
our results were unchanged. Nearly 50% of patients with
non-GN CKD had diabetic nephropathy, implying severe
diabetes that may disproportionately contribute to CVD
risk in a way not fully accounted for by the propensity
score. To address this, we performed sensitivity analyses
in which we repeated the matching algorithm in sub-
groups based on diabetic status. As expected, we observed
substantially higher CVD risk in diabetics compared to
non-diabetics (21.4% vs. 6.2–8.2% respectively), but in
both subgroups CV event rates were similar in GN and
non-GN patients. Using a systematic and comprehensive
analysis strategy, we have shown that CKD patients with
GN are at a high absolute 3-year risk of CVD, but that this
is explained by the severity of renal dysfunction and the
accumulation of traditional CV risk factors rather than be-
ing attributed to the GN disease itself.
Because CVD is such an important cause of mortality
in patients with CKD [8, 9, 14, 21, 29], our findings have
substantial implications to the clinical care and manage-
ment of CVD in GN patients. Cardiac risk stratification
is especially important in younger patients, being neces-
sary to implement appropriate prevention strategies, and
in the assessment for kidney transplantation. Our
unmatched GN group had a high 8.2% absolute 3-year
risk of CVD despite a mean age of only 58 years, and
72–80% having no prior history of DM or CVD. Preven-
tion strategies such as statin therapy are not likely to be
employed as routine treatment for these patients, owing
to their lack of comorbidities and relatively young age.
However, our study shows that GN patients with CKD
are at high absolute CV risk, greater than 10% over
10 years, and therefore should be considered for statin
therapy according to the KDIGO lipid guidelines [30].
Although biomarkers of inflammation and vascular
health have been associated with CVD in the general
CKD population, our study offers novel insights into the
possibility that there are differences in the predictive
value of biomarkers in those with GN compared to non-
GN CKD. Our interaction analyses suggested a non-
significant trend towards CRP being a stronger CVD risk
factor in CKD patients with GN, and uACR and tropo-
nin being more important CVD risk factors in non-GN
CKD. Reasons for this are not clear, but may include in-
flammation and CRP being more pronounced in GN
thereby playing a more prominent role in the develop-
ment of CVD; albuminuria reflecting local renal
pathology in GN patients instead of being a marker of
endothelial dysfunction and CV risk as it is in the gen-
eral and all-cause CKD populations; and [5, 6, 10, 31].
more common non-CVD causes of increased tropo-
nin in patients with GN [32–34]. These results
require confirmation in larger studies with sufficient
power to investigate and explain differential associa-
tions between biomarkers and CVD risk within sub-
groups of CKD etiology.
Our GN group comprised of patients with advanced
kidney disease with a mean eGFR of 27 ml/min/1.73 m2
and who were not on immunotherapy, which must be
considered in the generalizability of our results. Com-
pared to other cohorts of patients with active GN such
as the Toronto GN registry [35], our patients are older,
with lower eGFR and lower levels of proteinuria, consist-
ent with study enrolment at a later stage in the disease
process. Low levels of CRP (2.4 μg/L) and IL-6 (3.55 μg/
L) were seen in the GN patients and were comparable to
levels in the matched non-GN group. Our study clearly
shows that when glomerular disease becomes quiescent,
GN patients are at comparable CV risk to other patients
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with CKD and similar CV risk factors. Future research is
required to determine if our results apply at an early
stage of glomerular disease, in which renal function is
preserved but more severe inflammation or proteinuria
have been hypothesized to disproportionately contribute
to CVD in the absence of other CV risk factors.
Although no study has specifically addressed this issue,
the results of Mahmoodi et al. suggest this may not be
the case. In this study of 298 nephrotic patients with
mean eGFR of 59 ml/min/1.73 m2, the absolute risk of
CVD was high at 1.48% per year, however this was dis-
proportionately dominated by those with diabetic ne-
phropathy. In the subgroup of GN patients without
diabetes or prior CVD, the risk was only 0.82% per year,
suggesting that even amongst nephrotic patients with
preserved renal function, the development of CVD is
substantially related to pre-existing CV risk factors [2].
The considerably higher incidence of CV events seen in
our GN cohort compared to that of Mahmoodi, at 3.12%
per year, is probably a result of older age, lower eGFR
and greater accumulation of traditional CV risk factors.
If future research confirms our finding that CVD in
patients with early GN is predominantly determined by
prior traditional risk factors and level of renal function,
then GN patients without other comorbidities and
normal renal function may not have an increased
absolute risk of CVD. This finding would substantially
impact therapeutic decisions regarding primary
prevention strategies with statins at earlier stages of
glomerular disease.
Our study has several other limitations that should be
considered in the interpretation of the results. The spe-
cific type of glomerular disease was unknown in ap-
proximately 50% of the GN patients. This limits our
ability to draw conclusions about specific GN types and
CV risk. Certain types of GN such as minimal change
disease may not be associated with CVD due to infre-
quent nephrotic flares with long periods of intermittent
disease quiescence [2, 27]. However, it is unlikely
that such patients would have been included in our
GN cohort since progression to advanced CKD is
unlikely in the absence of persistent ongoing pro-
teinuria and disease activity. There was no available
information about cigarette smoking as a CV risk
factor, and so this could not be included in our mul-
tivariable models. Centrally adjudicated peripheral
vascular disease outcome events were not available
for analysis; however, our composite CV outcome
event definition is nonetheless consistent with that
used in major CV clinical trials [36–38]. Finally, it is
possible that the GN and non-GN groups will differ
in CV events occurring late after study enrolment,
and this difference would not be detected by the
3 year follow up of our study.
Conclusions
We have shown that GN patients with CKD and de-
creased eGFR who are not on active immunosuppressive
therapy have a high 9.2% 3 year risk of CV events. How-
ever, this risk does not appear to be different from other-
wise similar CKD patients without GN, suggesting that
the elevated risk of CVD in GN patients may be attribut-
able to prior CV risk factors and level of kidney function
rather than the GN disease itself.
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